Indianapolis-based Eli Lilly intends to build a biomanufacturing facility that would cost $6.5 billion to build and employ 4,000+ in the greater Houston area.

More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries to maintain its dominance in the GLP-1 market.

Indianapolis-based Eli Lilly intends to build a biomanufacturing facility that would cost $6.5 billion to build and employ 4,000+ in the greater Houston area.